Literature DB >> 8983889

Meropenem permeation through the outer membrane of Pseudomonas aeruginosa can involve pathways other than the OprD porin channel.

F J Pérez1, C Gimeno, D Navarro, J García-de-Lomas.   

Abstract

The outer membrane protein (OMP) OprD is the major channel through which carbapenems permeate the outer membrane of Pseudomonas aeruginosa. In this study, we analyzed the OMP profiles of several P. aeruginosa clinical isolates showing diminished susceptibility to imipenem while remaining susceptible to meropenem. All these isolates lacked OprD or showed a reduced expression of this porin. Susceptibility to meropenem was thus independent of the level of OprD expression, indicating that the antimicrobial could be taken up via an alternative route. The level of expression of OprC (70 kD) was also unrelated to meropenem susceptibility. Nevertheless, OMPs OprF and OprE were expressed by all isolates, suggesting that in the absence of OprD, these porins might be involved in the permeation of meropenem.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8983889     DOI: 10.1159/000239444

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  9 in total

1.  C-terminal region of Pseudomonas aeruginosa outer membrane porin OprD modulates susceptibility to meropenem.

Authors:  S F Epp; T Köhler; P Plésiat; M Michéa-Hamzehpour; J Frey; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Effect of antibiotic heterogeneity on the development of infections with antibiotic-resistant gram-negative organisms in a non-intensive care unit surgical ward.

Authors:  Yoshio Takesue; Hiroki Ohge; Mitsuru Sakashita; Takeshi Sudo; Yoshiaki Murakami; Kenichiro Uemura; Taijiro Sueda
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

3.  Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates.

Authors:  H Pai; J Kim; J Kim; J H Lee; K W Choe; N Gotoh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Alterations of OprD in carbapenem-intermediate and -susceptible strains of Pseudomonas aeruginosa isolated from patients with bacteremia in a Spanish multicenter study.

Authors:  Alain A Ocampo-Sosa; Gabriel Cabot; Cristina Rodríguez; Elena Roman; Fe Tubau; María D Macia; Bartolomé Moya; Laura Zamorano; Cristina Suárez; Carmen Peña; María A Domínguez; Gabriel Moncalián; Antonio Oliver; Luis Martínez-Martínez
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

5.  In vitro activities of faropenem against 579 strains of anaerobic bacteria.

Authors:  Hannah M Wexler; Denise Molitoris; Shahera St John; Ann Vu; Erik K Read; Sydney M Finegold
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 6.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

7.  Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems.

Authors:  T Köhler; M Michea-Hamzehpour; S F Epp; J C Pechere
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

8.  High-resolution genotyping of Pseudomonas aeruginosa strains linked to acute post cataract surgery endophthalmitis outbreaks in India.

Authors:  Prashanth Kenchappa; Virender S Sangwan; Niyaz Ahmed; K Rajender Rao; Avinash Pathengay; Annie Mathai; Tarannum Mansoori; Taraprasad Das; Seyed E Hasnain; Savitri Sharma
Journal:  Ann Clin Microbiol Antimicrob       Date:  2005-12-12       Impact factor: 3.944

9.  oprC Impairs Host Defense by Increasing the Quorum-Sensing-Mediated Virulence of Pseudomonas aeruginosa.

Authors:  Pan Gao; Kai Guo; Qinqin Pu; Zhihan Wang; Ping Lin; Shugang Qin; Nadeem Khan; Junguk Hur; Haihua Liang; Min Wu
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.